Neoadjuvant Treatment of Colon Cancer

This study has been completed.
Herlev Hospital
Information provided by (Responsible Party):
Vejle Hospital Identifier:
First received: April 14, 2010
Last updated: May 20, 2015
Last verified: March 2014

This study will investigate

  • the effect of preoperative combination chemotherapy in patients with locally advanced colon cancer with mutation in the KRAS, BRAF or PIK3CA gene
  • the effect of preoperative combination chemotherapy in combination with biological treatment in patients without mutation in the KRAS, BRAF or PIK3CA gene.

Condition Intervention Phase
Colon Cancer
Drug: Oxaliplatin
Drug: Capecitabine
Biological: Panitumumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Neoadjuvant Chemotherapy and Biological Treatment for Patients With Locally Advanced Colon Cancer

Resource links provided by NLM:

Further study details as provided by Vejle Hospital:

Primary Outcome Measures:
  • The frequency of patients requiring adjuvant chemotherapy based on the histological evaluation of the preparation from the operation. [ Time Frame: Within 1 week after surgery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Recurrence free survival [ Time Frame: Up to 2 years. ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: Up to 2 years. ] [ Designated as safety issue: No ]

Enrollment: 76
Study Start Date: April 2010
Study Completion Date: March 2015
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Chemotherapy only
Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
Drug: Oxaliplatin
130 mg/m2 intravenously on day 1 of a 3-weekly cycle
Drug: Capecitabine
2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
Chemotherapy + biological treatment
Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
Drug: Oxaliplatin
130 mg/m2 intravenously on day 1 of a 3-weekly cycle
Drug: Capecitabine
2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
Biological: Panitumumab
9 mg/kg intravenously on day 1 of a 3-weekly cycle


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically verified locally advanced T3 or T4 colon cancer assessed by CT scan
  • Analysis of KRAS, BRAF, PIK3CA
  • Age ≥18 år
  • Performance status ≤ 2
  • Hematology

    • ANC ≥ 1.5x10^9/l. Thrombocytes ≥ 100x10^9/l.
  • Biochemistry

    • Bilirubinaemia ≤ 3 x UNL. ALAT ≤ 5 x UNL
  • Consent to translational research
  • Fertile women must present a negative pregnancy test and use secure birth control during and 3 months after treatment.
  • Written and orally informed consent.

Exclusion Criteria:

  • Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment, active severe infections or other concurrent disease.
  • Peripheral neuropathy NCI grade >1
  • Other malignant disease within 5 years prior to enrollment, except basal cell squamous carcinoma of the skin and cervical carcinoma-in-situ
  • Other investigational treatment within 30 days prior to treatment start
  • History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
  • Bleeding tumors
  • Hypersensitivity to one or more of the substances
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01108107

Department of Oncology, Herlev Hospital
Herlev, Denmark, DK-2730
Dept. of Oncology, Hilleroed Hospital
Hilleroed, Denmark, 3400
Department of Oncology, Vejle Hospital
Vejle, Denmark, DK-7100
Sponsors and Collaborators
Vejle Hospital
Herlev Hospital
Principal Investigator: Anders Jakobsen, DMSc Vejle Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vejle Hospital Identifier: NCT01108107     History of Changes
Other Study ID Numbers: S-20100014 
Study First Received: April 14, 2010
Last Updated: May 20, 2015
Health Authority: Denmark: Ethics Committee

Keywords provided by Vejle Hospital:
Colon cancer
Neoadjuvant treatment
KRAS mutation
BRAF mutation
PIK3CA mutation
Possibly avoid chemotherapy after operation

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 26, 2016